IG RD 001

Drug Profile

IG RD 001

Alternative Names: IG-RD-001; Leucet; Petasites; Petasol butenoate; Petasol butenoate complex; Tesalin; ZE 339

Latest Information Update: 06 Jun 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Zeller
  • Developer Indigene Pharmaceuticals; Zeller
  • Class Antiallergics; Antimigraines; Phytotherapies
  • Mechanism of Action Leukotriene inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Seasonal allergic rhinitis

Most Recent Events

  • 31 Dec 2008 Discontinued - Phase-III for Seasonal allergic rhinitis in Germany (PO)
  • 19 Sep 2003 Launched for Seasonal allergic rhinitis in Switzerland (PO)
  • 02 Sep 2003 Registered for Seasonal allergic rhinitis in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top